Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Announces Ryzodeg Approved in Japan


Tuesday, 25 Dec 2012 02:10am EST 

Novo Nordisk A/S announced that the Japanese Ministry of Health, Labor and Welfare has approved Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes. Ryzodeg is a soluble formulation of Tresiba (insulin degludec), a once-daily new generation basal insulin analogue with an ultra-long duration of action, and NovoRapid (insulin aspart which in the United States is marketed under the NovoLog brand name). Ryzodeg can be administered once or twice daily with the main meal(s). In global 'treat-to-target' studies supporting the new drug application, where Ryzodeg was compared with NovoMix, Ryzodeg demonstrated a significantly lower risk of nocturnal hypoglycaemia while achieving equivalent reductions in HbA1c. In Japan, Ryzodeg will be available in FlexTouch, Novo Nordisk A/S's latest prefilled insulin pen, which has an auto-injector mechanism, and in Penfill for Novo Nordisk A/S's durable insulin pens. 

Company Quote

257.9
0.4 +0.16%
31 Jul 2014